ALCLS Cellectis SA

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social

(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)

PARIS, 04 févr. 2026 (GLOBE NEWSWIRE) --

Place de cotation : Euronext Growth

ISIN code: FR0010425595

DateNombre total d’actions composant le capital socialNombre total de droits de vote
31/01/2026100 590 994105 825 481



Pour de plus amples informations sur Cellectis, veuillez contacter :

Contacts média :

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33,

Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Contact pour les relations avec les investisseurs :

Arthur Stril, Chief Financial Officer & Chief Business Officer, +1 (347) 809 5980,

Pièce jointe



EN
04/02/2026

Underlying

ALCLSCellectis SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Cellectis SA

IFX INFINEON TECHNOLOGIES AG
LOGN LOGITECH INTERNATIONAL S.A.
ALLIX WALLIX GROUP SA
ALTR ALTRI SGPS SA
MRN MERSEN SA
ALCLS CELLECTIS SA
ELG ELMOS SEMICONDUCTOR SE
TPE PVA TEPLA AG
COTN COMET HOLDING AG
CICN CICOREL HOLDING S.A.
SAVE SAVENCIA SA
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
AIXA AIXTRON SE
PFV PFEIFFER VACUUM TECHNOLOGY AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
SEM SEMPERIT HOLDING AG
CFT COMPAGNIE FINANCIERE TRADITION
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
WAF SILTRONIC AG
MELE MELEXIS NV
NOD NORDIC SEMICONDUCTOR ASA
SMHN SUESS MICROTEC AG
VACN VAT GROUP AG
IDR INDRA SISTEMAS S.A. CLASS A
XFAB X-FAB SILICON FOUNDRIES SE
ASML ASML HOLDING NV
STM STMICROELECTRONICS NV
VOS VOSSLOH AG
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
JEN JENOPTIK AG
FPE3 FUCHS PETROLUB SE
HDF HYDROGENE DE FRANCE
IOS IONOS GROUP SE
ARM ARM HOLDINGS PLC
AMS AMS-OSRAM AG
SPG SPRINGER NATURE AG & CO. KGAA
DSPW DOOSAN SKODA POWER A.S.
IFCN INFICON HOLDING AG
YOUNI YOUNITED FINANCIAL S.A.
03/20/26 March 20, 2026 1 EN
IFX INFINEON TECHNOLOGIES AG
LOGN LOGITECH INTERNATIONAL S.A.
ALLIX WALLIX GROUP SA
ALTR ALTRI SGPS SA
MRN MERSEN SA
ALCLS CELLECTIS SA
ELG ELMOS SEMICONDUCTOR SE
ACX ACERINOX SA
TPE PVA TEPLA AG
COTN COMET HOLDING AG
CICN CICOREL HOLDING S.A.
SAVE SAVENCIA SA
SOI SOITEC SA
ASM ASM INTERNATIONAL N.V.
AIXA AIXTRON SE
PFV PFEIFFER VACUUM TECHNOLOGY AG
ATS AT & S AUSTRIA TECHNOLOGIE & SYSTEMTECHNIK AKTIENGESELLSCHAFT
SEM SEMPERIT HOLDING AG
CFT COMPAGNIE FINANCIERE TRADITION
SBO SCHOELLER-BLECKMANN OILFIELD EQUIPMENT AG
WAF SILTRONIC AG
MELE MELEXIS NV
NOD NORDIC SEMICONDUCTOR ASA
SMHN SUESS MICROTEC AG
VACN VAT GROUP AG
IDR INDRA SISTEMAS S.A. CLASS A
XFAB X-FAB SILICON FOUNDRIES SE
ASML ASML HOLDING NV
STM STMICROELECTRONICS NV
VOS VOSSLOH AG
BESI BE SEMICONDUCTOR INDUSTRIES N.V.
JEN JENOPTIK AG
FPE3 FUCHS PETROLUB SE
HDF HYDROGENE DE FRANCE
IOS IONOS GROUP SE
ARM ARM HOLDINGS PLC
AMS AMS-OSRAM AG
SPG SPRINGER NATURE AG & CO. KGAA
DSPW DOOSAN SKODA POWER A.S.
IFCN INFICON HOLDING AG
YOUNI YOUNITED FINANCIAL S.A.
03/20/26 March 20, 2026 1 FR
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
03/20/26 March 20, 2026 1 EN
Martial Descoutures ... (+2)
  • Martial Descoutures
  • Oussema Denguir
03/20/26 March 20, 2026 1 FR
 PRESS RELEASE
Free
ALCLS CELLECTIS SA

Cellectis Reports Full Year 2025 Financial Results and Provides a Busi...

Cellectis Reports Full Year 2025 Financial Results and Provides a Business Update Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 populationIn target Phase 2 population: 100% of patients became eligible to transplantPivotal Phase 2 first interim analysis expected in Q4 2026BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) ongoing Best-in-class dual allogeneic CAR-T cell product targeting CD20 & CD22At current dose level, 88% ORR; 63% CR rate after 2+ prior lines of thera...

March 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch